Lupin launches Molnupiravir under brand name Molnulup to treat COVID-19

Lupin has launched Molnupiravir in India under the brand name Molnulup, the drug that has been given Emergency Use Authorisation (EUA) by the Drug Controller General of India (DCGI) for treatment of adult patients with COVID-19, a company statement notified.

The statement said that pre-clinical and clinical data have shown Molnupiravir to be effective against the most common SARS-CoV-2 variants including Gamma, Delta and Mu variants. The pill should be initiated as soon as possible after a diagnosis of COVID-19 and within five days of onset of symptoms.

Commenting on the development, Rajeev Sibal, President – India Region Formulations (IRF) said, “The approval for Molnulup is timely as India is again experiencing an upward spike in COVID-19 incidences. In the past two years since COVID-19 has emerged, there is a need for an oral antiviral medicine that can be prescribed by the healthcare practitioners and then taken by the patients conveniently at home. Through our strong distribution network, we will make Molnulup readily available at pharmacies pan-India to meet patient demand.”